Interview with Harald Stock, CEO, Grünenthal
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Address: Walter-Benjamin-Platz 6, D-10629 Berlin,Germany
Tel: +49 30 327787-0
The firm has a nationwide presence. Since an increasing number of medical mandates – for instance, in the field of law governing drugs and medical devices – are not confined to national boundaries, we work with law firms based in other European countries which specialize in similar fields. We primarily work with our EuMedLex partners. The company advises on all branches of medical law and also on related aspects pertaining to public law, corporate law and competition law.They offer competence and experience in the field of medical law, ensuring that clients can base their personal and entrepreneurial decisions on a reliable juridical foundation. The firm is independent, pointing out legal boundaries to clients – and looking for ways to achieve their goals in spite of these. The company is multidisciplinary: The special fields of medical law will direct a client to appropriately proven attorneys in the law firm. Nonetheless daily technical discussions with each other always keep the lawyers abreast of the latest developments in the fields.
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Roche, once a true pharmaceutical company, is now recognized by its capacity to create a unique business model that allowed to become the world’s largest biotech company with truly differentiated…
Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The…
Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community.…
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for…
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
See our Cookie Privacy Policy Here
